List of Exforge Hct drug patents

Exforge Hct is owned by Novartis.

Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.

Exforge Hct has a total of 3 drug patents out of which 0 drug patents have expired.

Exforge Hct was authorised for market use on 30 April, 2009.

Exforge Hct is available in tablet;oral dosage forms.

The generics of Exforge Hct are possible to be released after 16 November, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents
May, 2023

(3 months from now)

US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
May, 2023

(3 months from now)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
Nov, 2023

(9 months from now)

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 30 April, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EXFORGE HCT before it's patent expiration?
More Information on Dosage

EXFORGE HCT family patents

8

United States

4

China

3

Korea, Republic of

3

Japan

3

Peru

3

European Union

2

Hong Kong

2

Brazil

2

Australia

2

Mexico

2

Argentina

2

South Africa

2

Russia

2

Norway

2

Canada

2

New Zealand

2

Taiwan, Province of China

2

Ecuador

1

Austria

1

Morocco

1

Chile

1

Poland

1

Malaysia

1

Spain

1

Germany

1

Israel

1

Cyprus

1

Tunisia

1

Slovenia

1

Portugal

1

Egypt

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic